Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States

BACKGROUND: Ustekinumab has been recently approved for the treatment of moderately to severely active ulcerative colitis (UC). The registry trials for ustekinumab in UC demonstrated efficacy and safety, but data on real-world outcomes are limited. We describe the effectiveness and safety of ustekinu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Simon J, Krugliak Cleveland, Noa, Akiyama, Shintaro, Zullow, Samantha, Yi, Yangtian, Shaffer, Seth R, Malter, Lisa B, Axelrad, Jordan E, Chang, Shannon, Hudesman, David P, Rubin, David T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802405/
https://www.ncbi.nlm.nih.gov/pubmed/36777067
http://dx.doi.org/10.1093/crocol/otab002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802405/
https://www.ncbi.nlm.nih.gov/pubmed/36777067
http://dx.doi.org/10.1093/crocol/otab002

Ejemplares similares